MonashHealth

Research Support Services
Monash Health
Level 2, I Block
Monash Medical Centre
246 Clayton Road
Clayton Victoria 3168

Tel (03) 9594 4611
Fax (03) 9594 6306
Email: research@monashhealth.org

12 June 2018

Dr Elizabeth Baker
Newborn Research
The Royal Women's Hospital
20 Flemington Rd
Parkville Victoria 3050

Dear Researcher,

Study title: Human Amnion Epithelial Cells for Prevention of Bronchopulmonary Dysplasia: A Phase 1 Dose Escalation Study

NMA HREC Reference Number: HREC/18/MonH/168
Monash Health Ref: 18-0000-180A

The Monash Health HREC reviewed the above application at the meeting held on 05 April 2018 In addition, the HREC is satisfied that the responses to our correspondence of 06 April 2018 have been sufficiently addressed.

The HREC approved the above application on the basis of the information provided in the application form, protocol and supporting documentation.

This reviewing HREC is accredited by the Consultative Council for Clinical Trial Research under the single ethical review system.

Approval

The HREC approval is from 12 June 2018

Approval is given in accordance with the research conforming to the *National Health and Medical Research Council Act 1992* and the *National Statement on Ethical Conduct in Human Research (2007)*. The HREC has ethically approved this research according to the Memorandum of Understanding between the Consultative Council and the participating organisations conducting the research.

Approval is given for this research project to be conducted at the following sites and campuses:

- Monash Health
- Hudson Institute of Medical Research
- Royal Women's Hospital
- University of Melbourne

You must comply with the following conditions:

The Chief Principal Investigator is required to notify the Manager, Human Research Ethics Committees, Monash Health of:

1. Any change in protocol and the reason for that change together with an indication of ethical implications (if any)

2. Suspected Unexpected Serious Adverse Reactions (SUSARs) involving a Monash Health participant or a participant at site that Monash Health has provided HREC Review.
3. Serious Adverse Events (SAEs) that occur with a Monash Health participant or with a participant from a site that Monash Health has provided HREC review that are considered by the Investigator as being definitely related, probably related, possibly related and unknown.
4. Any unforeseen events that might affect continued ethical acceptability of the project.
5. Any expiry of the insurance coverage provided in respect of sponsored trials.
6. Discontinuation of the project before the expected date of completion, giving reasons.
7. Any change in personnel involved in the research project including any study member resigning from Monash Health &/or the study team.

At the conclusion of the project or every twelve months if the project continues, the Principal Investigator is required to complete and forward an annual progress report to the Committee.

Reminders to submit annual progress report forms will be forwarded to the researcher.

The Coordinating Principal Investigator is responsible for notifying Principal Investigators. The Coordinating Principal Investigator and Principal Investigators should forward a copy of this letter to their site's Research Governance Officer.

Approved documents

Documents reviewed and approved at the meeting were:

Document	*Version*	*Date*
Human Research Ethics Application	AU/1/161539	21 March 2018
Victorian-Specific Module: Vic Specific Module		21 March 2018
Investigator CV of Dr. Elizabeth Baker		
Medical Board of Australia Certificate of Registration – Dr. Elizabeth Baker		
Master Parent/Guardian Information Sheet/Consent Form: Amnion Cells and BPD	7	07 June 2018
Protocol: Amnion Cells and BPD: Dose Escalation Protocol	5	21 May 2018

Site-Specific Assessment (SSA)

SSA authorisation is required at all sites participating in the study. SSA must be authorised at a site before the research project can commence.

The completed Site-Specific Assessment Form and a copy of this ethics approval letter must be submitted to the Research Governance Officer for authorisation by the Chief Executive or delegate. This applies to each site participating in the research.

If you should have any queries about your project please contact Deborah Dell or Julie Gephart by email deborah.dell@monashhealth.org /julie.gephart@monashhealth.org

The HREC wishes you and your colleagues every success in your research.

Yours sincerely

DEBORAH DELL
Manager, Human Research Ethics Committee
& Research Support Services

Attachments:

Cc: Ms Sue Kirsa and Ms Helen Kopp, Therapeutics Committee
Cc: Peter Davis

Please Note: It is requested that correspondence be forwarded electronically to research@monashhealth.org with the local Monash Health reference number inserted.

Checklist: Post-ethics approval requirements that must be met before a research project can commence at a study site.

Please ensure that as a PI (including the CPI) the following are completed at each study site.

Requirements	**Yes/No/NA**
Ethics approval notification The PI must send a copy to the RGO at that study site.	Yes
HREC Review Only Indemnity The PI must forward a copy of the signed HREC Review Only Indemnity to the RGO at that study site.	N/A
CTN Acknowledgement for Commercially Sponsored Studies The PI must forward a copy of the CTN Acknowledgement to Research Support Services.	No
CTN Lodgement for Collaborative Group/Investigator Driven Studies The PI or nominated delegate is requested to make an appointment with the Monash Health Research Support Services contact for the study deborah.dell@monashhealth.org or michael.kios@monashhealth.org so that the lodgment may be completed by both the investigator and Research Support Services. The banking details for payment to the TGA will need to be brought along to this appointment, in order to finalise notification to the TGA. The fee for lodging a CTN is $335.	Yes
SSA authorisation notification The PI must forward the SSA form and attached documents (e.g. CTRA) to the RGO so the authority approving the conduct of the trial, at that site, can complete and sign.	Yes
Radiation If applicable, the RGO must contact the Medical Physicist so that the study may be notified to the Radiation Risk Section of the Department of Health and Human Services.	N/A
Other Commonwealth statutory requirements Ensure compliance with the following e.g. Office of the Gene Technology Regulator, NHMRC Licensing Committee, NHMRC Cellular Therapies Advisory Committee.	N/A